Tag Archives: Patent Law

PTO Announces Requirements for Expedited Appeals for Small Entities

Posted on September 16, 2015 by Warren Woessner

For some years, I have complained that the lack of a timely appeal process to the Board (“PTAB”) effectively removes the appeal process as a prosecution tool. The average pendency of an appeal to the Board from a rejection arising … Continue reading →

Posted in Appeals, Patent Reform Legislation, s.102 | Tagged ip, Patent Law | Leave a comment

Sandoz Launches First Biosimilar Drug in U.S.

Posted on September 4, 2015 by Warren Woessner

A new chapter in the generics/innovator wars began Thursday as Sandoz, Novartis’ generics division launched its Neupogen biosimilar, Zarxio, in the U.S. at about a 15-30% discount from the price of Neupogen. While biosimilars have been marketed in Europe since 2006, Congress … Continue reading →

Posted in Biosimilars | Tagged Biosimilars, biotechnology, biotechnology law, biotechnology news, intellectual property, ip, Novartis, Patent Law, patents, Sandoz, Warren Woessner, Zarxio | Leave a comment

Another Claim Bites the Dust left by Teva v. Sandoz

Posted on September 3, 2015 by Warren Woessner

Although the jury found the claims valid, and the Fed. Cir. affirmed, this decision, which found that the claims were not insolubly ambiguous, was revisited by the Fed. Cir. While there are pages on issue preclusion, in the end, the … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged biotechnology, biotechnology law, Dow v Nova, Federal Circuit, intellectual property, ip, Patent Law, patents, Warren Woessner | 2 Comments

Chisum Patent Academy – Seattle 2015 Seminar Takeaways

Posted on August 19, 2015 by Warren Woessner

This is a guest post from Donald Chisum and Janice Mueller. On August 12-14, 2015, the Chisum Patent Academy held a three-day seminar at the historic Mayflower Park Hotel in downtown Seattle, Washington to discuss and debate current developments in … Continue reading →